Last week, attendees of Sage Bionetworks’ 3rd Annual Congress came to San Francisco with the bold charge to speed up drug discovery and ready to stand on the shoulders of the previous two Congresses to take the nascent open source biology movement from a thinking to a doing stage. Pitched as “Building Better Models of … Continue reading “Taking Open Biology to the Next Level: Notes from the Sage Congress”
Author: Stephen Friend
Stephen H. Friend is president, CEO and a co-founder of Sage Bionetworks, an international genomic research collaborative. He was previously a Senior Vice President at Merck, where he led Merck’s Basic Cancer Research efforts. In 2005, he led the Advanced Technologies and Oncology groups to firmly establish molecular profiling activities throughout Merck’s laboratories around the world, as well as to coordinate oncology programs from Basic Research through phase IIA clinical trials.
Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Five Biotechnologies That Will Fade Away This Decade
[Editor’s Note: This is part of a series of posts from Xconomists and other technology leaders from around the country who are weighing in with the Top 5 innovations they’ve seen in their respective fields the past 10 years, or the Top 5 disruptive technologies that will impact the next decade.] We look at amazement … Continue reading “Five Biotechnologies That Will Fade Away This Decade”